Condition: Solid Tumor · Advanced Solid Tumor · Solid Tumor, Adult · Sponsor: NiKang Therapeutics, Inc.
The goal of the Dose Escalation phase of the study is to evaluate the safety, tolerability, pharmacokinetics (PK) and preliminary anti-tumor activity to determine the preliminary recommended dose for expansion (RDE) of NKT3964 in adults with advanced or metastatic solid tumors. The goal of the Expansion phase of the study is to evaluate the preliminary anti-tumor activity of NKT3964 at the RDE based on objective response rate (ORR) and determine the preliminary recommended Phase 2 dose (RP2D).
This description comes directly from the study's public registry record.
Sponsor Contact · (302) 596-8654 · clinicaltrials@nikangtx.com
Always discuss trial participation with your own doctor first.
| University of Arkansas Medical School | Little Rock, Arkansas, United States | Recruiting |
| University of California - Los Angeles | Los Angeles, California, United States | Not Yet Recruiting |
| UCSF | San Francisco, California, United States | Withdrawn |
| SCRI at HealthOne | Denver, Colorado, United States | Recruiting |
| Florida Cancer Specialists & Research Institute | Lake Mary, Florida, United States | Terminated |
| AdventHealth Cancer Institute | Orlando, Florida, United States | Recruiting |
| Emory Winship Cancer Institute | Atlanta, Georgia, United States | Recruiting |
| Augusta University | Augusta, Georgia, United States | Not Yet Recruiting |
| University of Kansas | Fairway, Kansas, United States | Withdrawn |
| Dana Farber Cancer Institute | Boston, Massachusetts, United States | Recruiting |
| John Theurer Cancer Center at Hackensack UMC | Hackensack, New Jersey, United States | Recruiting |
| Sidney Kimmell Cancer Center - Jefferson Health | Philadelphia, Pennsylvania, United States | Recruiting |
+ 7 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06586957